Delivery Order SPE2DB20D2104-SPE2DB25FNBSU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,025.05 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a small-value transaction under a larger federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,533.49 to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) on September 17, 2025, with an ultimate completion date of September 18, 2025. This firm fixed price delivery order was competitively awarded without any set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical supply transaction within DLA's...
- The Defense Logistics Agency awarded a delivery order valued at $10,862.72 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) with a firm fixed-price structure. This non-set-aside competitive award was issued on May 30, 2025, with an ultimate completion date of June 2, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30-tablet units, with a contract ceiling value of $13,740.06. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract is scheduled for ultimate completion on September 12, 2025, and will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $60,140.57 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on September 11, 2025, with an ultimate completion date of September 12, 2025. The contract requires performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside provisions applied to the award. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,012.98 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on September 11, 2025, with completion anticipated by September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $46,224.65 for Xeljanz XR 11 mg tablets (30-count unit of use packaging) on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's ongoing supply of pharmaceutical products to federal medical procurement needs. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $20,512.96 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) under a firm fixed price contract. The award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a non-competitive, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $51,847.92 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) under a firm fixed-price contract type. This non-set-aside award was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $3,198.50, was competitively awarded without set-aside designation and is scheduled for completion by August 22, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNBSUDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count unit dose) with a ceiling value of $5,920.47 under a firm fixed price contract type. The award was made on September 26, 2025, with an ultimate completion date of September 29, 2025. This non-set-aside delivery order represents a small-value pharmaceutical procurement supporting federal medical supply needs, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates its critical role as a major pharmaceutical distributor for the Defense Health Agency and other federal healthcare systems, with consistent delivery of specialty medications and medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 9/26/25 |